鹰瞳科技-B：2025年中期报告

Beijing Airdoc Technology Co., Ltd. (A joint stock company incorporated in the People’s Republic of China with limited liability)Stock Code2251 CONTENTS目錄2Corporate Information6Financial Summary7Management Discussionand Analysis44Other Information65Independent Review Report67Interim Condensed ConsolidatedStatement of Profit or Loss68Interim Condensed ConsolidatedStatement of Comprehensive Income69Interim Condensed ConsolidatedStatement of Financial Position71Interim Condensed ConsolidatedStatement of Changes in Equity72Interim Condensed ConsolidatedStatement of Cash Flows76Notes to Interim CondensedConsolidated Financial Information105Definitions and Glossary ofTechnical Terms CORPORATE INFORMATION BOARD OF DIRECTORS Executive Directors Mr. ZHANG Dalei()(Chairman and chief executive officer)Ms. WANG Lin()Dr. HE Chao()(resigned on 29 July 2025)Mr. QIN Yong()Mr. WEI Yubo()(appointed on 27 June 2025) 20257 2920256 27 Independent Non-executive Directors Dr. WU Yangfeng()Dr. HUANG Yanlin()Mr. NG Ho Yin Owen() SUPERVISORS 20255 2620255 26 Mr. WEI Yubo()(resigned on 26 May 2025)Ms. BAI Huihui()Dr. LUO Ting()Ms. LUO Yujie()(appointed on 26 May 2025) AUDIT COMMITTEE Mr. NG Ho Yin Owen()(Chairman)Dr. HUANG Yanlin()Dr. WU Yangfeng() REMUNERATION AND APPRAISALCOMMITTEE Dr. HUANG Yanlin()(Chairman)Mr. NG Ho Yin Owen()Ms. WANG Lin() NOMINATION COMMITTEE Mr. ZHANG Dalei()(Chairman)(ceased on 29 July 2025)Dr. HUANG Yanlin()(Chairman)(effective from 29 July 2025)Dr. WU Yangfeng()Ms. WANG Lin()(effective from 29 July 2025) 20257 2920257 2920257 29 STRATEGY COMMITTEE Mr. ZHANG Dalei()(Chairman)Mr. NG Ho Yin Owen()Dr. WU Yangfeng() ESG COMMITTEE 20257 2920257 29 Mr. ZHANG Dalei()Ms. WANG Lin()Mr. QIN Yong()(effective from 29 July 2025)Dr. HE Chao()(ceased on 29 July 2025) AUTHORIZED REPRESENTATIVES Mr. ZHANG Dalei()Ms. SO Lai Shan() JOINT COMPANY SECRETARIES 20251 2020251 20 Ms. YANG Wenting()(ceased on 20 January 2025)Ms. WANG Xinfeng(effective from 20 January 2025)Ms. SO Lai Shan()(ACG (CS, CGP) HKACG (CS, CGP)) HEAD OFFICE, REGISTERED OFFICEAND PRINCIPAL PLACE OF BUSINESS INTHE PRC 22421 Room 21, 4th Floor, Building 2, A2 YardWest Third Ring North RoadHaidian DistrictBeijingPRC PRINCIPAL PLACE OF BUSINESS INHONG KONG 33191901 Room 1901, 19/F, Lee Garden One33 Hysan AvenueCauseway BayHong Kong H H SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong HONG KONG LEGAL ADVISER 12151501 Kwok Yih & ChanSuite 1501, 15/F.Bank of America Tower12 Harcourt RoadCentralHong Kong PRC LEGAL ADVISER 2022–31 Zhong Lun Law Firm22–31/F, South Tower of CP Center20 Jin He East AvenueChaoyang DistrictBeijingPRC AUDITOR 97927 Ernst & Young Certified Public AccountantsRegistered Public Interest Entity Auditor27/F, One Taikoo Place979 King’s RoadQuarry BayHong Kong STOCK CODE 22512251 www.airdoc.com COMPANY WEBSITE www.airdoc.com FINANCIAL SUMMARY MANAGEMENT DISCUSSION AND ANALYSIS管理層討論與分析 BUSINESS OVERVIEW As an industry leader, we are focused on leveraging AItechnology to develop a dual-engine strategy built onprecise detection and innovative treatment, with a view tooffering an integrated diagnosis and treatment solutionsdesigned for chronic and ophthalmic diseases. Precise Detection Segment AI(SaMD) Leveraging on our proprietary AI-empowered retina-baseddeep learning algorithm platform, we maintain our leadershipin the early detection, diagnosis, and health risk assessmentof chronic and ophthalmic diseases. As one of the pioneersin detection services harnessing the Retinal AI technology inChina, our products are widely used in medical institutionsat all levels and consumer healthcare service scenarios. Ourkey product offerings include AI-based SaMDs, health riskassessment solutions, and AI detection hardware, whichcreate an integrated software and hardware ecosystem forAI-empowered detection. —AI Based on the existing detection product system, during theReporting Period, the Company had further expanded theboundaries of its detection business by successfullydeveloping and launching a new-generation physiologicalstress resilience assessmentproduct, the “Airdoc StressResilience Assessment”. Based on wireless sensingtechnology (non-contact detection) and multimodal AIalgorithm technology and leveraging the Company’sexpertise in image recognition, large model algorithms, andtechnological accumulation in deep learning, the productcan capture users’ physiological signals in real time,calculate the changes in the autonomic nervous systemunder external visual stimulation, and thereby provide anintelligent assessment of an individual’s stress state. It is aninnovative solution for non-contact health monitoring. MANAGEMENT DISCUSSION AND ANALYSIS Innovative Treatment Segment With our detection expertise, we have continued to expandinto the therapy business with a focus on myopia preventionand control as well as visual training. We have